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https://doi.org/10.1016/j.stemcr.2020.08.008SUMMARYHuman hematopoietic stem cells (HSCs) emerge in the aorta-gonad-mesonephros (AGM) region during Carnegie stages (CS) 14–17.
Although we previously reported that these HSCs can generate no less than 300 daughter HSCs, their actual number has never been es-
tablished. Here, we show that a single human AGM regionHSC can generate 600–1,600 functional daughter HSCs. The presence of HSCs
in the CS 17 liver in one case gave us a unique opportunity to describe a reduction of HSC self-renewal potential after liver colonization.
From a clinical perspective, the efficacy of long-term hematopoietic regeneration depends on HSC self-renewal capacity. We quantita-
tively show that this capacity dramatically declines in the umbilical cord blood compared with HSCs in the AGM region. A full appreci-
ation of the vast regenerative potential of the first human embryo-derived HSCs sets a new bar for generation of clinically useful HSCs
from pluripotent stem cells.INTRODUCTION
Previous analyses using transplantations into adult
NOD.Cg-Prkdcscid Il2rgtm1Wjl/Sz (NSG) mice showed that
the first human hematopoietic stem cells (HSCs) emerge
in the aorta-gonad-mesonephros (AGM) region duringCar-
negie stages (CS) 14–17 (developmental days 32–41) and
possess a substantial self-renewal potential (Ivanovs et al.,
2011, 2014). However, the actual number of daughter
HSCs could not be determined, as the dilution factor used
has never reached the limit required to precisely quantify
HSCs. Here, we have used a broader range of limiting dilu-
tions to determine the accurate number of daughter HSCs
generated by a single human embryo-derived HSC. We
have also assessed the self-renewal potential of umbilical
cord blood (UCB) HSCs, which are broadly used in clinical
settings to treat congenital and acquired hematological dis-
orders. This important quality of UCBHSCs has never been
quantitatively assessed before.RESULTS AND DISCUSSION
We performed three independent limiting-dilution trans-
plantation experiments with human AGM region cells
(Figure 1A). In each experiment, a single-cell suspension
prepared from an individual AGM region was split into
five equal parts and transplanted into five primary NSG
recipient mice. Each time, human repopulation was found
only in one out of five recipients, confirming that each
AGM region contained only one definitive HSC (IvanovsStem Cell Re
This is an open access artiet al., 2011). To assess daughter HSC numbers generated
by a single AGM region HSC, 5–9months after the primary
transplantation the bone marrow (BM) of each engrafted
primary recipient was retransplanted in limiting dilutions
into a cohort of 20 secondary recipients split into four
groups. Mice in each group received cell doses ranging
from 1/20 to 1/1,620 of total primary BM per recipient.
The secondary recipients were monitored for 5 months
and considered to be engrafted if at least 0.1% of peripheral
blood (PB) CD45+ cells were of human origin belonging to
both myeloid and lymphoid lineages.
In experiment 1, the AGM region (CS 16, developmental
day 37) was transplanted. The engrafted primary recipient
showed human multilineage hematopoietic chimerism
(5% and 31% in PB and BM, respectively) (Table S1). Five
months after the primary transplantation, serially diluted
BM cells from the repopulated primary recipient were re-
transplanted into 20 secondary recipients. All secondary re-
cipients that received 1/20, 1/60, or 1/180 of total primary
BM showed human long-term multilineage PB engraft-
ment (31% ± 14.0%, 14% ± 10.0%, and 3.6% ± 3.80%,
respectively). Dilutions of 1/540 showed repopulation in
only three of five secondary recipients, with markedly
lower PB chimerism (1.1% ± 0.06%) (Figure 1B and Table
S2). Using extreme limiting dilution analysis (ELDA) (Hu
and Smyth, 2009), we calculated that a single human
AGM region HSC produced z605 (95% CI: 254–1,440)
daughter HSCs (Figure S1A).
In experiment 2, the AGM region (CS 17, developmental
day 41) was transplanted. The engrafted recipient showed
high-level human multilineage chimerism (62% and 92%ports j Vol. 15 j 811–816 j October 13, 2020 j ª 2020 The Authors. 811




Figure 1. Self-renewal Capacity of Human AGM Region, Embryonic Liver, and UCB HSCs
(A) A single-cell suspension prepared from an individual human AGM region was transplanted in equal portions into five primary NSG
recipient mice. BM cells from the engrafted primary recipient were retranslated into four cohorts of secondary recipients at dilutions
ranging from 1/20 to 1/1,620 of total primary BM per recipient.
(B) Secondary repopulation dynamics over 5 months by BM cells from a primary NSG recipient reconstituted by a single AGM region HSC
(experiment 1).
(C) Secondary repopulation at 5 months by BM cells from primary NSG recipients reconstituted by a single AGM region HSC (left chart) or by
liver HSCs (right chart; experiment 2).
(D) Secondary repopulation at 5 months by BM cells from primary NSG recipients reconstituted byz10–20 UCB HSCs (50,000 CD34+ cells)
each (cumulative of three independent transplantations).
Human CD45+ cell chimerism was assessed in the PB of secondary recipients 2, 3, 4, and 5 months post transplantation. Circles represent
individual NSG recipient mice. Tissue source and engraftment levels in primary NSG recipients (PB and BM) are indicated in the top left
corner of each chart. Dilutions of primary BM cells transplanted per secondary recipient are indicated at the bottom of each chart. See also
Tables S1 and S2 and Figure S1.in PB and BM, respectively) (Table S1 and Figure 2). Six
months after the transplantation, the BM from the primary
repopulated recipient was retransplanted into secondary
recipients. Five months later, all secondary recipients that
received 1/60, 1/180, 1/540, and 1/1,620 dilutions showed
human long-term multilineage PB chimerism (54% ±
16.1%, 44% ± 6.1%, 29% ± 12.2%, and 16% ± 6.8%, respec-
tively) (Figure 1C, left chart, and Table S2). Saturated repo-
pulation revealed that in this case the single AGM region
HSC produced in excess of 1,620 daughter HSCs.812 Stem Cell Reports j Vol. 15 j 811–816 j October 13, 2020In experiment 3, the AGM region (CS 15, developmental
day 33) transplantation resulted in high-level human mul-
tilineage hematopoietic engraftment of one recipient (PB
and BMhuman chimerism 50% and 96%, respectively) (Ta-
ble S1). Nine months later, the BM of this recipient was re-
transplanted. After 5 months, all secondary recipients
transplanted with 1/60 and 1/180 primary BM dilutions
showed human long-term multilineage PB chimerism
(6.7% ± 7.51% and 5.0% ± 7.92%, respectively). Four of
five secondary recipients transplanted with 1/540 dilutions
A B
C D E
Figure 2. Human Long-Term Multilineage Hematopoietic Repopulation of a Primary NSG Recipient Mouse Engrafted with a Single
AGM Region HSC
(A) Human lymphoid (B, T, and NK cell) engraftment in the mouse PB, BM, and spleen.
(B) Human myeloid (total, granulocyte, and monocyte) engraftment in the mouse PB, BM, and spleen.
(C) Human erythroid engraftment in the mouse BM.
(D) Human platelet engraftment in the mouse PB.
(E) Human T cell populations in the mouse thymus and PB.
These representative flow-cytometry plots correspond to experiment 2. Please note that on the plots showing BM repopulation, murine
erythroid cells were not excluded, which explains the discrepancy with the percentage of human CD45+ cells reported in the text (92%). See
also Table S1.showed 0.2% ± 0.07% PB chimerism. Dilutions of 1/1,620
gave no engraftment (only two of five secondary recipients
survived) (Table S2). In this case, a single AGM region HSC
produced z730 (95% CI: 313–1,699) daughter HSCs
(Figure S1C).
Unexpectedly, the transplantation of CS 17 embryonic
liver cells (from the embryo used in experiment 2) into
two NSG recipients gave long-term multilineage hemato-
poietic repopulation in both mice. Previously, we observed
a complete lack ofHSCs in the liver up until at least CS 17 in
26 human embryos analyzed (Ivanovs et al., 2011). In this
experiment, one of the two recipients showed PB and BM
chimerism (40% and 94%, respectively) 6 months aftertransplantation and was used for a secondary transplanta-
tion experiment (Table S1). The other recipient initially
showed multilineage engraftment, but later developed
graft-versus-host disease and was excluded from further
analysis. All secondary recipients that received 1/60 and
1/180 dilutions showed long-term multilineage PB chime-
rism (11% ± 3.7% and 3.8% ± 2.42%, respectively). Four of
five secondary recipients transplantedwith 1/540 dilutions
showed PB chimerism (0.5% ± 0.39%). Only two of five sec-
ondary recipients transplanted with 1/1,620 dilutions
showed low engraftment levels (0.3% ± 0.47%) (Figure 1C,
right chart, and Table S2), suggesting that the liver-derived
HSCs generatedz880 (95% CI: 401–1,941) daughter HSCsStem Cell Reports j Vol. 15 j 811–816 j October 13, 2020 813
during the 6 month period within the primary recipient
(Figure S1B). This figure could be overestimated, as both
primary recipients were repopulated and thus each could
contain more than one liver HSC. Taken together, the
self-renewal properties of liver HSCs were inferior to the
AGM region HSCs of the same embryo.
We then assessed the self-renewal potential of human
UCB HSCs. In two independent experiments, cohorts of
five NSG recipients were transplanted with CD34+ cells iso-
lated from fresh UCB using anti-human CD34 magnetic
beads. Each primary recipient received 2,500 CD34+ cells,
a dose containing only one or two HSCs (McDermott
et al., 2010). In one experiment, all five recipients showed
long-term engraftment 4 months after transplantation,
and in the other experiment three of five recipients were
engrafted (average PB chimerism was 0.6% ± 0.45%). At
this point, we selected one primary recipient that showed
the highest repopulation level from each experiment:
mouse 1, with human PB and BM chimerism of 0.19%
and 5.1%, respectively, and mouse 2, with PB and BM
chimerism of 0.54% and 6.2%, respectively. The BM from
these primary recipients was retransplanted independently
into secondary recipients in dilutions of 1/20, 1/60, 1/180,
and 1/540. Lack of engraftment in these two secondary
transplantation experiments indicated that the dilution
range of primary BM cells used in the experiments with
AGM region cells appears to be too high to determine the
self-renewal potential of UCB HSCs.
Therefore, we set up three additional independent exper-
iments with higher UCB CD34+ cell doses and lower dilu-
tion ranges (experiments 4–6). In each experiment,
50,000 UCB CD34+ cells were transplanted per recipient,
which is equivalent to 10–20 HSCs per mouse (McDermott
et al., 2010). All primary recipients showed high-level PB
engraftment (28%–72%) 5 months after transplantation
(Table S1). From each experiment, the primary recipient
with the highest human PB chimerism (72%, 33%, and
28%) was chosen. The BM of each primary recipient was
then retransplanted in dilutions ranging from 1/12 to 1/
60 (Figure 1D). All six secondary recipients transplanted
with 1/12 dilutions showed an average PB chimerism of
2.7% ± 2.54%. Two of four secondary recipients trans-
planted with 1/25 dilutions showed an average PB chime-
rism of 0.3% ± 0.39%. Three of six secondary recipients
transplanted with 1/60 of total primary BM per recipient
showed an average PB chimerism of 0.3% ± 0.51% (Table
S2). Statistically, this suggests that the transplantation of
10–20 UCB HSCs per recipient gave z33 (95% CI: 17–67)
daughter HSCs per primary recipient 5 months later (Fig-
ure S1D). Thus, in striking contrast to AGM region HSCs,
UCB HSCs possess much lower self-renewal capacity,
enabling their maintenance without substantial expan-
sion. Limited self-renewal capacity of UCB HSCs has been814 Stem Cell Reports j Vol. 15 j 811–816 j October 13, 2020also reported by others, but using less efficient NOD/
SCID recipients (Guenechea et al., 2001; Liu et al., 2010;
McKenzie et al., 2006).
Overall, our study provides an accurate quantitative
comparison between the self-renewal potential of the first
emerging HSCs in the human embryo and those in the
UCB at birth. The actual production of daughter HSCs by
an individual AGM region HSC reaches 600–700, and in
one case wasmore than 1,620. The differences observed be-
tween embryos likely arise fromgenetic variability. Possibly
not by coincidence, the embryo whose AGM region HSCs
showed the highest daughter HSC production also showed
unusually early HSC colonization of the embryonic liver.
By direct comparison of AGM region and liver HSCs with
the same genetic background, we found that both the repo-
pulation levels and the self-renewal capacity of liver HSCs
were inferior compared with the AGM region HSCs (880
versus 1,620 daughter HSCs, respectively). Previously,
except for one case of multilineage long-term engraftment
by cultured CS 17 liver (Easterbrook et al., 2019), liver cell
transplantations from 26 human embryos up to CS 17
gave no repopulation. A dramatic decline in the self-
renewal capacity is clearly observed in UCB HSCs
compared with AGM region HSCs. Whether this has
already started in the liver requires further systematic anal-
ysis at later developmental stages. Notably, the repopula-
tion potential of mouse HSCs declines between the fetal
liver and the adult BM stages (Holyoake et al., 1999; Nico-
lini et al., 1999).
Adult BM and UCB HSCs are successfully used in clinical
transplantations (Gluckman et al., 1989; Good et al., 1969).
To enhance the safety and predictability of clinical HSC
transplantations, there is a need to generate readily avail-
able human HSCs (Daley, 2007). HSC expansion was
achieved in vitro (Fares et al., 2014; Gupta et al., 2020; Wil-
kinson et al., 2019), and long-term repopulating hemato-
poietic cells were produced from pluripotent stem cells
and endothelial cells using gene manipulations (Ivanovs
et al., 2017). Our study sets a new bar for the self-renewal
potential of human HSCs that can be generated in vitro.
Molecular mechanisms underlying the exceptional regen-
erative capacity of human AGM region HSCs require
further elucidation.EXPERIMENTAL PROCEDURES
Human Embryonic Tissues and Umbilical Cord Blood
Human embryonic tissues were obtained immediately after elec-
tive termination of pregnancy using mifepristone and misopros-
tol. The study was approved by the Lothian Research Ethics Com-
mittee. Before tissue specimens were obtained, each patient gave
informed consent for the use of embryonic tissues. The develop-
mental stage of human embryos was determined according to
the Carnegie staging system (O’Rahilly and Müller, 1987). Embry-
onic tissue dissection and single-cell suspension preparation were
performed as previously described (Ivanovs et al., 2011). FreshUCB
was obtained from the Edinburgh Reproductive Tissue Biobank. Fi-
coll-Paque (STEMCELL Technologies) was used to separate mono-
nuclear cells. CD34+ cells were isolated by employing the Miltenyi
Biotec magnetic cell separation technique.
Animals
NSG mice were bred within the University of Edinburgh (Edin-
burgh,UK) according to the provisions of theAnimal (Scientifi Pro-
cedures) Act 1986 under the project licence granted by the Home
Office (UK). Mice were kept under specific-pathogen-free condi-
tions in individually ventilated cages. Up to 6 h before transplan-
tation with human cells, 6–8 week old female NSG mice received
a sublethal total body irradiation dose of 3.5 Gy at a rate of 0.75
Gy/min from a 137Cs source (GSR D1 g-irradiator, Gamma-Service
Medical). Animals were transplanted with cells intravenously via
the tail vein.
Primary Murine Recipient Bone Marrow
The BM was flushed out from the bones and a single-cell suspen-
sion was prepared by gentle pipetting. A cell fraction associated
with endosteum was obtained from bones after treatment with
1 mg/mL collagenase/dispase and 0.12 mg/mL DNase I at 37C
for 40 min with gentle shaking and added to the flushed-out BM
fraction. To calculate the proportion of total BM transplanted
into secondary recipients, we used previously reported data on
the distribution of BM cells in different mouse bones (Boggs,
1984).
Flow-Cytometry Analysis
The followingmouse anti-humanmonoclonal antibodies (all from
BD) were used for flow-cytometry analysis: CD3-APC, PE and
PerCP (clones SK7 and SP34-2), CD4-APC and APC-Cy7 (clone
RPA-T4), CD8-PE and PE-Cy7 (clone RPA-T8), CD11b-PE-Cy7
(clone ICRF44), CD13-APC (clone WM15), CD14-APC and APC-
Cy7 (clones M5E2 and MfP9), CD19-PE (clone HIB19), CD33-PE
(cloneWM53), CD34-APC (clone 8G12), CD38-FITC and PE (clone
HIT2), CD41a-FITC (clone HIP8), CD45-Biotin, FITC, and V450
(clone HI30), CD66b-FITC (clone G10F5), CD94-APC (clone HP-
3D9), CD235a-APC (clone GA-R2), IgM-Biotin (clone G20-127),
ab TCR-FITC (clone WT31), and gd TCR-PE (clone 11F2). The Hu-
man FcR Blocking Reagent (Miltenyi Biotec) and anti-mouse
CD16/32 purified monoclonal antibody (clone 93) (eBioscience)
were used to prevent unwanted binding of antibodies to Fc recep-
tors. All antibodies and reagents listed abovewere used at final con-
centrations either recommended by the manufacturer or deter-
mined by titration in-house. 7-Amino-actinomycin (eBioscience)
was used for dead cell exclusion. A FACSCalibur, LSRFortessa
(both from BD), or CyAn ADP (Dako) instrument was used for
flow-cytometry analysis. Flow-cytometry data were analyzed
with FlowJo v.7.6.1 software (Tree Star).
Statistical Analysis
Data are presented as amean ± SD or a 95%CI. Validity tests for the
single-hit Poisson model and the limiting dilution analysis wereperformed using ELDA software (Hu and Smyth, 2009) available
at http://bioinf.wehi.edu.au/software/elda/ (Figure S1).SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/
10.1016/j.stemcr.2020.08.008.
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Figure S1. Calculation of Daughter HSC Numbers. Related to Figure 1. 
(A) Experiment 1 (AGM region). Number of harvested BM mononuclear cells: 41,000,000. Estimated total 
number of BM mononuclear cells: 102,500,000. 
(B) Experiment 2 (Liver). Number of harvested BM mononuclear cells: 37,000,000. Estimated total number of 
BM mononuclear cells: 92,500,000 
(C) Experiment 3 (AGM region). Number of harvested BM mononuclear cells: 54,000,000. Estimated total 
number of BM mononuclear cells: 160,000,000. 
(D) Experiments 4–6 (UCB). Number of harvested BM mononuclear cells: 36,000,000. Estimated total number 
of BM mononuclear cells: 90,000,000. 
ELDA is a software application for limiting dilution analysis in extreme data situations when some data sets give 
zero negative or positive responses. The method is particularly suitable for stem cell analysis. The bone marrow 
from each primary recipient was harvested from 12 bones (two femora, tibiae, fibulae, humeri, radii, and ulnae) 
and pelvis. The total number of mononuclear cells in the recipient was calculated assuming that the proportion of 
BM harvested represents ≈40% of total BM (Boggs, D.R. (1984). The total marrow mass of the mouse: a 
simplified method of measurement. Am J Hematol 16, 277-286). For each experiment, the first table is populated 
with cell numbers corresponding to different dilutions (dose), total number of transplanted mice for each dilution 
(tested), and number of engrafted mice (response). The second table shows the estimated number of BM 
mononuclear cells containing one HSC and the 95% CI (lower and upper). The total number of HSCs in primary 
recipients was calculated by dividing total BM mononuclear cell number by the cell number containing one HSC. 
In the graphs, the natural logarithm of the nonengrafted mice fraction was plotted against the cell dose transplanted 
per recipient (shown by open circles). Down-pointing triangles represent the data value with zero negative or 
positive responses (all recipients for the same dilution are either nonengrafted or engrafted). The solid diagonal 
line indicates the mean HSC number per cell dose transplanted and dotted lines show the 95% CI. HSC numbers 
transplanted per recipient mouse (λ) can be calculated from the formula λ= –ln(fraction of nonengrafted mice). 
From here, –ln(0.37)≈1, which means that the dose of transplanted cells yielding ≈37% of nonengrafted recipient 
mice contains ≈1 HSC. The cell dose containing one HSC can be determined on the graph by plotting an imaginary 
horizontal line from the y axis at –1 to intercept the solid diagonal line and then by drawing a vertical line from 







































Supplemental Table Captions 
Table S1. Primary Recipient Engraftment Data. Related to Figure 1 and Figure 2.  
Table S2. Secondary Recipient Engraftment Data. Related to Figure 1. 
 
 
